Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 15, 2019 09:42 ET | Source: OncBioMune, L.L.C.

OncBioMune Announces Compelling Pre-clinical Data for its CD71-targeted Chemotherapy, PGT, in Models of Lung, Pancreatic and Ovarian Cancers

BATON ROUGE, La., July 15, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
May 30, 2019 09:08 ET | Source: OncBioMune, L.L.C.

OncBioMune Announces Initial In Vitro Proof-of-Concept Data for PGT in a Multi-Drug Resistant Ovarian Cancer Model

BATON ROUGE, La., May 30, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
May 01, 2019 09:28 ET | Source: OncBioMune, L.L.C.

OncBioMune Announces Agreement with CATO BioVentures as a Strategic Investor in Support of CD71-Targeted Therapy for Refractory Cancers

BATON ROUGE, La., May 01, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
March 19, 2019 08:30 ET | Source: OncBioMune, L.L.C.

Phase 2 Trial of OncBioMune’s Immunotherapy Cancer Vaccine ProscaVax for Prostate Cancer Patients in Active Surveillance Now Open for Enrollment

BATON ROUGE, La., March 19, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
February 28, 2019 08:29 ET | Source: OncBioMune, L.L.C.

OncBioMune Announces Consulting Agreement with CATO Research LLC for Developing PGT, a Protein Drug Complex Targeting CD71 for Refractory Cancers

BATON ROUGE, La., Feb. 28, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
January 28, 2019 08:54 ET | Source: OncBioMune, L.L.C.

Dr. Mitesh Borad Joins OncBioMune Scientific Advisory Board

BATON ROUGE, La., Jan. 28, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
January 09, 2019 08:28 ET | Source: OncBioMune, L.L.C.

OncBioMune Announces Former Puma Biotechnology Executive and Genentech Veteran Brian Barnett, M.D., as Chief Executive Officer

BATON ROUGE, La., Jan. 09, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
December 07, 2018 09:00 ET | Source: OncBioMune, L.L.C.

Site Visit Planned for December 19, 2018 to Initiate Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer

BATON ROUGE, La., Dec. 07, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
November 08, 2018 09:08 ET | Source: OncBioMune, L.L.C.

OncBioMune Phase 2 Clinical Trial to Begin Enrollment; Company Announces Other Developments and Corporate Milestones

BATON ROUGE, La., Nov. 08, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
October 31, 2018 09:00 ET | Source: OncBioMune, L.L.C.

OncBioMune CEO Dr. Jonathan Head Speaking at 2018 Global Summit on Genitourinary Malignancies

BATON ROUGE, La., Oct. 31, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...